

# Pier Mannuccio Mannucci

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3312698/pier-mannuccio-mannucci-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

309  
papers

14,102  
citations

60  
h-index

113  
g-index

329  
ext. papers

16,002  
ext. citations

6.6  
avg, IF

7.08  
L-index

#	Paper	IF	Citations
309	Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice.. <i>Phlebology</i> , <b>2022</b> , 2683555211068948	2	2
308	Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.. <i>Pathology Research and Practice</i> , <b>2022</b> , 231, 153796	3.4	1
307	Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2.. <i>Haematologica</i> , <b>2022</b> , 107, 785-786	6.6	0
306	Pharmaceutical pricing in Europe: time to take the right direction.. <i>Internal and Emergency Medicine</i> , <b>2022</b> , 1	3.7	1
305	An ecological alliance against air pollution and cardiovascular disease <b>2022</b> , 1, 19-23		
304	Gene transfer in hemophilia A: not cogent yet <b>2022</b> , 1, 7-8		0
303	Pharmaceutical patenting in the European Union: reform or riddance. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 1	3.7	0
302	Prophylactic management of patients with von Willebrand disease.. <i>Therapeutic Advances in Hematology</i> , <b>2021</b> , 12, 20406207211064064	5.7	2
301	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. <i>Haemophilia</i> , <b>2021</b> , 27, e525-e529	3.3	1
300	Von Willebrand disease type 2N: An update. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 909-916	15.4	6
299	Sustainable and personalized nutrition: From earth health to public health. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 86, 12-16	3.9	4
298	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. <i>Acta Diabetologica</i> , <b>2021</b> , 58, 1225-1236	3.9	2
297	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. <i>Haemophilia</i> , <b>2021</b> , 27, e441-e449	3.3	1
296	Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. <i>Blood Reviews</i> , <b>2021</b> , 50, 100849	11.1	0
295	Post-mortem findings in vaccine-induced thrombotic thombocytopenia. <i>Haematologica</i> , <b>2021</b> , 106, 2291-2293	6.2	20
294	COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	24
293	Bleeding Disorders in Primary Fibrinolysis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1

292	What changed in the Italian internal medicine and geriatric wards during the lockdown. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 84, 97-100	3.9	
291	Intelligent game engines for home exercises (exergames) in boys with haemophilia. <i>Haemophilia</i> , <b>2021</b> , 27, e151-e154	3.3	2
290	Pharmacist-driven medication recognition/ reconciliation in older medical patients. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 83, 39-44	3.9	3
289	Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 389-400	3.7	7
288	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. <i>Age and Ageing</i> , <b>2021</b> , 50, 498-504	3	0
287	Community and hospital pharmacists in Europe: encroaching on medicine?. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 7-10	3.7	1
286	Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 255-258	3.7	7
285	Authors' Reply to Brunetti et al. "Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?". <i>Drugs and Aging</i> , <b>2021</b> , 38, 93-94	4.7	1
284	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 621-625	4.5	1
283	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. <i>Clinical Interventions in Aging</i> , <b>2021</b> , 16, 1251-1264	4	1
282	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 1	3.7	3
281	Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19: comment. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 1	3.7	0
280	Integrated care: easy in theory, harder in practice?. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 1	3.7	0
279	The never ending success story of tranexamic acid in acquired bleeding. <i>Haematologica</i> , <b>2020</b> , 105, 1201-1205	6.6	10
278	Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?. <i>Drugs and Aging</i> , <b>2020</b> , 37, 585-593	4.7	12
277	Traffic-related air pollution and the coronavirus pandemia: shadows and lights. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	4
276	Acquired von Willebrand syndrome: focused for hematologists. <i>Haematologica</i> , <b>2020</b> , 105, 2032-2037	6.6	19
275	Hemophilia therapy: the future has begun. <i>Haematologica</i> , <b>2020</b> , 105, 545-553	6.6	60

274	Conflicts of interest in medicine: a never-ending story. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 357-359	3.7	2
273	Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 303-309	5.9	8
272	Cardiovascular health and ambient air pollution: lower is not enough. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	2
271	Defensive medicine: Everything and its opposite. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 74, 117-118	3.9	3
270	Comorbidity does not mean clinical complexity: evidence from the RePoSI register. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 621-628	3.7	7
269	Use and prescription appropriateness of drugs for peptic ulcer and gastroesophageal reflux disease in hospitalized older people. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 459-465	2.8	7
268	The dark age of Italian general practice research - An Italian matter. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 73, 98-99	3.9	1
267	Pain and Frailty in Hospitalized Older Adults. <i>Pain and Therapy</i> , <b>2020</b> , 9, 727-740	3.6	8
266	SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. <i>EBioMedicine</i> , <b>2020</b> , 59, 102951	8.8	108
265	Aging with Hemophilia: The Challenge of Appropriate Drug Prescription. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019056	3.2	6
264	Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 65, 51-57	3.9	10
263	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. <i>Medical Principles and Practice</i> , <b>2019</b> , 28, 501-508	2.1	4
262	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. <i>Vascular Pharmacology</i> , <b>2019</b> , 113, 92-93	5.9	2
261	Novel evidence for a greater burden of ambient air pollution on cardiovascular disease. <i>Haematologica</i> , <b>2019</b> , 104, 2349-2357	6.6	45
260	Factor VIII replacement is still the standard of care in haemophilia A. <i>Blood Transfusion</i> , <b>2019</b> , 17, 479-486	6.6	22
259	Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. <i>Blood Transfusion</i> , <b>2019</b> , 17, 385-390	3.6	11
258	New therapies for von Willebrand disease. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 590-595	3.1	3
257	New therapies for von Willebrand disease. <i>Blood Advances</i> , <b>2019</b> , 3, 3481-3487	7.8	18

256	Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	13
255	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 54, 60-64	3.9	4
254	Primary hyperfibrinolysis: Facts and fancies. <i>Thrombosis Research</i> , <b>2018</b> , 166, 71-75	8.2	11
253	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 778-790	15.4	14
252	Viral safety of coagulation factor concentrates: memoirs from an insider. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 630-633	15.4	3
251	The importance of ABO blood group in pharmacokinetic studies in haemophilia A. <i>Haemophilia</i> , <b>2018</b> , 24, e122-e123	3.3	4
250	Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. <i>Archives of Gerontology and Geriatrics</i> , <b>2018</b> , 74, 169-173	4	9
249	Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. <i>Haemophilia</i> , <b>2018</b> , 24, e6-e10	3.3	7
248	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 87-97	2.8	8
247	Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 54, 53-59	3.9	14
246	Polypharmacy in older adults with severe haemophilia. <i>Haemophilia</i> , <b>2018</b> , 24, e1-e3	3.3	3
245	Mitigation of air pollution by greenness: A narrative review. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, 1-5	3.9	28
244	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. <i>Haemophilia</i> , <b>2018</b> , 24, 726-732	3.3	5
243	Ageing successfully with haemophilia: A multidisciplinary programme. <i>Haemophilia</i> , <b>2018</b> , 24, 57-62	3.3	12
242	Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 1191-1200	3.7	32
241	Miracle of haemophilia drugs: Personal views about a few main players. <i>Haemophilia</i> , <b>2018</b> , 24, 557-562	3.3	18
240	More on air pollution and venous thromboembolism. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, e11	3.9	1
239	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 405-410	4.1	4

238	Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. <i>Haemophilia</i> , <b>2017</b> , 23, 182-187	3.3	12
237	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , <b>2017</b> , 232, 98-104	3.2	13
236	Reply to the letter by Iorio. <i>Haemophilia</i> , <b>2017</b> , 23, e248-e249	3.3	3
235	Antipsychotic prescription and mortality in hospitalized older persons. <i>Psychogeriatrics</i> , <b>2017</b> , 17, 397-405	6	
234	Progress in the contemporary management of hemophilia: The new issue of patient aging. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 43, 16-21	3.9	18
233	Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. <i>Haemophilia</i> , <b>2017</b> , 23, e348-e353	3.3	6
232	SIPPET: methodology, analysis and generalizability. <i>Haemophilia</i> , <b>2017</b> , 23, 353-361	3.3	20
231	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. <i>Blood</i> , <b>2017</b> , 129, 1245-1250	2.2	28
230	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 46, 6-10	3.9	13
229	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. <i>Blood</i> , <b>2017</b> , 130, 1757-1759	2.2	31
228	Management of Hemophilia in Older Patients. <i>Drugs and Aging</i> , <b>2017</b> , 34, 881-889	4.7	4
227	Use of non-steroidal anti-inflammatory drugs and analgesics in a cohort of hospitalized elderly patients: Results from the REPOSI study. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 38, e11-e12	3.9	1
226	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. <i>Archives of Gerontology and Geriatrics</i> , <b>2017</b> , 69, 21-30	4	7
225	Health Effects of Ambient Air Pollution in Developing Countries. <i>International Journal of Environmental Research and Public Health</i> , <b>2017</b> , 14,	4.6	182
224	The increased demand for plasma-derived factor VIII in Italy. <i>Blood Transfusion</i> , <b>2017</b> , 15, 279-280	3.6	4
223	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2017</b> , 72, 395-402	6.4	35
222	Uncertain thrombophilia markers. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 25-30	7	21
221	Association between particulate air pollution and venous thromboembolism: A systematic literature review. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 27, 10-3	3.9	30

220	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , <b>2016</b> , 7, 80083-80090	3.3	21
219	Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1330-6	15.4	11
218	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	25
217	The safety of pharmacologic options for the treatment of persons with hemophilia. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1391-400	4.1	10
216	Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 32, 38-42	3.9	5
215	Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 526-32	5.3	24
214	Direct oral anticoagulants and venous thromboembolism. <i>European Respiratory Review</i> , <b>2016</b> , 25, 295-302	3.8	18
213	Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study. <i>Drugs and Aging</i> , <b>2016</b> , 33, 647-54	4.7	2
212	Von Willebrand factor (Vonvendi): the first recombinant product licensed for the treatment of von Willebrand disease. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 825-30	2.8	27
211	Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. <i>Clinical Advances in Hematology and Oncology</i> , <b>2016</b> , 14 Suppl 11, 2-15	0.6	20
210	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 305-13	3.7	7
209	Introduction and overview. <i>Blood Reviews</i> , <b>2015</b> , 29 Suppl 1, S1-3	11.1	
208	Effects on health of air pollution: a narrative review. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 657-62	3.7	148
207	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 243-9	3.9	10
206	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 330-7	3.9	18
205	Understanding organ dysfunction in thrombotic thrombocytopenic purpura. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 715-8	14.5	12
204	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. <i>Thrombosis Research</i> , <b>2015</b> , 136, 851-4	8.2	22
203	Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, e47-8	3.9	1

202	The Health and Economic Burden of Air Pollution. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 931-2	2.4	16
201	Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 696-704	3.9	47
200	Half-life extension technologies for haemostatic agents. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 165-767		26
199	Classic thrombophilic gene variants. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 885-9	7	72
198	Management of Bleeding Associated with New Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 788-801	5.3	14
197	Gender difference in drug use in hospitalized elderly patients. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 483-90	3.9	18
196	Impact on human health of climate changes. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 1-5	3.9	66
195	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 847-52	3.9	1
194	Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. <i>Haemophilia</i> , <b>2014</b> , 20 Suppl 6, 2-16	3.3	10
193	Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2014</b> , 39, 511-5	2.2	50
192	Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 617-23	3.9	62
191	Inhibitor eradication with rituximab in haemophilia: where do we stand?. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 600-8	4.5	39
190	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 148-54	13.4	113
189	Prescription drug use among older adults in Italy: a country-wide perspective. <i>Journal of the American Medical Directors Association</i> , <b>2014</b> , 15, 531.e11-531.e15	5.9	15
188	Factor VIII Deficiency or Hemophilia A: Clinical Bleeding and Management <b>2014</b> , 45-56		
187	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. <i>Blood</i> , <b>2014</b> , 123, 4037-44	2.2	100
186	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , <b>2014</b> , 124, 1715-26	2.2	220
185	Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 427-31	7	48



184	The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 757-65	2.8	11
183	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. <i>Nature Medicine</i> , <b>2014</b> , 20, 466	50.5	2
182	Pediatric requirements in Europe stymie help for hemophilia. <i>Nature Medicine</i> , <b>2014</b> , 20, 117	50.5	6
181	Making clinical decisions on the basis of RODIN. <i>Haemophilia</i> , <b>2014</b> , 20, e174-5	3.3	
180	Emerging drugs for hemophilia B. <i>Expert Opinion on Emerging Drugs</i> , <b>2014</b> , 19, 407-14	3.7	4
179	Integrated postural analysis in children with haemophilia. <i>Haemophilia</i> , <b>2014</b> , 20, 263-7	3.3	9
178	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 723-34	3.7	95
177	Haematology clinic: Haemophilia A. <i>Hematology</i> , <b>2014</b> , 19, 181-2	2.2	11
176	Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 735-47	3.7	15
175	The European standards of Haemophilia Centres. <i>Blood Transfusion</i> , <b>2014</b> , 12 Suppl 3, s525-30	3.6	7
174	The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. <i>Blood Transfusion</i> , <b>2014</b> , 12 Suppl 3, s519-24	3.6	1
173	A certification/accreditation model for Haemophilia Centres in Italy. <i>Blood Transfusion</i> , <b>2014</b> , 12 Suppl 3, s505-9	3.6	2
172	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). <i>Haemophilia</i> , <b>2013</b> , 19, 76-81	3.3	72
171	Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. <i>Drugs and Aging</i> , <b>2013</b> , 30, 103-12	4.7	120
170	Is haemophilia B less severe than haemophilia A?. <i>Haemophilia</i> , <b>2013</b> , 19, 499-502	3.3	49
169	Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 285-7	3.9	10
168	Investigational drugs for coagulation disorders. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 945-53	5.9	10
167	Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 177-82	4.5	53

166	Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management. <i>Haemophilia</i> , <b>2013</b> , 19, 344-8	3.3	9
165	Drug-drug interactions in a cohort of hospitalized elderly patients. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1054-60	2.6	41
164	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. <i>Blood</i> , <b>2013</b> , 122, 648-57	2.2	101
163	Acquired haemophilia A: a 2013 update. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1114-20	7	85
162	Recombinant factor VIIa as haemostatic therapy in advanced liver disease. <i>Blood Transfusion</i> , <b>2013</b> , 11, 487-90	3.6	4
161	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. <i>Blood Transfusion</i> , <b>2013</b> , 11, 533-40	3.6	11
160	Liver disease, coagulopathies and transfusion therapy. <i>Blood Transfusion</i> , <b>2013</b> , 11, 32-6	3.6	22
159	The demand for factor VIII and for factor IX and the toll fractionation product surplus management. <i>Blood Transfusion</i> , <b>2013</b> , 11 Suppl 4, s64-76	3.6	6
158	Present and future challenges in the treatment of haemophilia: a clinician's perspective. <i>Blood Transfusion</i> , <b>2013</b> , 11 Suppl 4, s77-81	3.6	12
157	The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade. <i>Haemophilia</i> , <b>2012</b> , 18 Suppl 2, 2-7	3.3	8
156	Clinical governance: many fancies, very few facts. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 3-4	3.7	
155	Getting rid of refractory hemophilia. <i>Blood</i> , <b>2012</b> , 119, 1326-7	2.2	1
154	How we choose factor VIII to treat hemophilia. <i>Blood</i> , <b>2012</b> , 119, 4108-14	2.2	60
153	Air pollution and cardiovascular disease. <i>Thrombosis Research</i> , <b>2012</b> , 129, 230-4	8.2	76
152	Health-related quality of life and psychological well-being in elderly patients with haemophilia. <i>Haemophilia</i> , <b>2012</b> , 18, 345-52	3.3	26
151	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. <i>Haemophilia</i> , <b>2012</b> , 18, e173-87	3.3	71
150	Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 505-10	4	13
149	Hemostatic defects in liver and renal dysfunction. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 168-73	3.1	11

148	Hemostatic defects in liver and renal dysfunction. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 168-173	3.1	37
147	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. <i>Blood</i> , <b>2012</b> , 120, 3383-3383	2.2	0
146	The coagulopathy of chronic liver disease. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 147-56	59.2	935
145	Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. <i>Journal of Comorbidity</i> , <b>2011</b> , 1, 28-44	4	132
144	Thrombogenicity and cardiovascular effects of ambient air pollution. <i>Blood</i> , <b>2011</b> , 118, 2405-12	2.2	127
143	Treatment of haemophilia: building on strength in the third millennium. <i>Haemophilia</i> , <b>2011</b> , 17 Suppl 3, 1-24	3.3	6
142	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 700-10	15.4	329
141	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 507-19	2.8	208
140	Old and new anticoagulant drugs: a minireview. <i>Annals of Medicine</i> , <b>2011</b> , 43, 116-23	1.5	39
139	Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. <i>Haemophilia</i> , <b>2010</b> , 16, 101-10	3.3	27
138	Co-morbidities and quality of life in elderly persons with haemophilia. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 522-33	4.5	81
137	Aspirin as antiplatelet agent in diabetes: Cons. <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 154-6	3.9	1
136	Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 254-9	3.9	8
135	Fine particulate: it matters. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 659-61	15.4	8
134	Red cells playing as activated platelets in thalassemia intermedia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 2149-51	15.4	18
133	Autoimmune hemophilia at rescue. <i>Haematologica</i> , <b>2009</b> , 94, 459-61	6.6	8
132	Activated Partial Thromboplastin Time. <i>Scandinavian Journal of Haematology</i> , <b>2009</b> , 25, 308-317		6
131	von Willebrand disease in the 21st century: current approaches and new challenges. <i>Haemophilia</i> , <b>2009</b> , 15, 1154-8	3.3	11

130	Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 780-6	15.4	107
129	Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 1809-15	15.4	88
128	Evidence-based recommendations on the treatment of von Willebrand disease in Italy. <i>Blood Transfusion</i> , <b>2009</b> , 7, 117-26	3.6	51
127	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. <i>Blood</i> , <b>2009</b> , 114, 3154-3154	3.3	70
126	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1450-2	15.4	7
125	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. <i>Haemophilia</i> , <b>2008</b> , 14, 444-53	3.3	70
124	Back to the future: a recent history of haemophilia treatment. <i>Haemophilia</i> , <b>2008</b> , 14 Suppl 3, 10-8	3.3	114
123	Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. <i>British Journal of Haematology</i> , <b>2008</b> , 75, 86-91	4.5	
122	Desmopressin: an historical introduction. <i>Haemophilia</i> , <b>2008</b> , 14 Suppl 1, 1-4	3.3	6
121	Understanding hemostasis and thrombosis : The lesson learnt from natural models. <i>Japanese Journal of Thrombosis and Hemostasis</i> , <b>2008</b> , 19, 85-91	0	
120	Prevention and treatment of major blood loss. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 2301-11	59.2	373
119	Reply:. <i>Hepatology</i> , <b>2007</b> , 45, 832-833	11.2	1
118	Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. <i>Haemophilia</i> , <b>2007</b> , 13, 373-9	3.3	74
117	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). <i>Haemophilia</i> , <b>2007</b> , 13 Suppl 5, 65-8	3.3	74
116	Thrombosis and bleeding disorders outside Western countries. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5 Suppl 1, 68-72	15.4	7
115	Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 1115-24	15.4	90
114	von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 1420-30	15.4	98
113	Short-term effects of air pollution on cardiovascular diseases: outcomes and mechanisms. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 2169-74	15.4	93

112	Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. <i>Haematologica</i> , <b>2007</b> , 92, 944-51	6.6	67
111	Need for randomized trials in hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 501-2	15.4	12
110	Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 721-3	15.4	66
109	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 2103-14	15.4	884
108	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. <i>Blood</i> , <b>2006</b> , 108, 1061-1061	2.2	
107	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. <i>Blood</i> , <b>2005</b> , 106, 1262-7	2.2	229
106	Thrombolytic therapy in acute myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 2806-7	15.4	
105	Localization and Function of Platelet ADAMTS-13.. <i>Blood</i> , <b>2005</b> , 106, 3967-3967	2.2	
104	Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 213-8	4.5	84
103	Ilsley Ingram. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 1219-1219	15.4	
102	Treatment of von Willebrand's Disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 683-94	59.2	390
101	Recessively inherited coagulation disorders. <i>Blood</i> , <b>2004</b> , 104, 1243-52	2.2	380
100	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. <i>Blood</i> , <b>2003</b> , 102, 2358-63	2.2	314
99	Overview of bleeding in cancer patients. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2003</b> , 33 Suppl 1, 44-5		6
98	The International Society for Thrombosis and Haemostasis owns its official journal: the future has begun!. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 1-2	15.4	15
97	Consistency of ADAMTS-13 activity assays: a moderately optimistic view. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 1880-1	15.4	8
96	AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 2065-9	15.4	20
95	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). <i>Haematologica</i> , <b>2003</b> , 88, 454-8	6.6	32

94	Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). <i>Haematologica</i> , <b>2003</b> , 88, 914-8	6.6	76
93	Venous thrombosis: the history of knowledge. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2002</b> , 32, 209-12		17
92	Venous thromboembolism in von Willebrand disease. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 378-9	7	35
91	How I treat patients with von Willebrand disease. <i>Blood</i> , <b>2001</b> , 97, 1915-9	2.2	135
90	Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. <i>Blood</i> , <b>2001</b> , 98, 2730-5	2.2	425
89	Venous thrombosis and anticoagulant therapy. <i>British Journal of Haematology</i> , <b>2001</b> , 114, 258-70	4.5	22
88	Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. <i>British Journal of Haematology</i> , <b>2001</b> , 114, 871-4	4.5	14
87	The hemophilias--from royal genes to gene therapy. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 1773-9	59.2	747
86	Use of prophylaxis to prevent complications of hemophilia. <i>Advances in Experimental Medicine and Biology</i> , <b>2001</b> , 489, 59-64	3.6	13
85	Treatment of von Willebrand disease. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 86, 149-53	7	8
84	The search for the causes of myocardial infarction. Introduction. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , <b>2001</b> , 2, 489		
83	Autoimmune bleeding disorders in cancer patients. <i>Haemostasis</i> , <b>2001</b> , 31 Suppl 1, 45-6		
82	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. <i>Haemophilia</i> , <b>2000</b> , 6 Suppl 1, 60-7	3.3	88
81	A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 1240-1246	4.5	1
80	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 1223-1229	4.5	
79	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 1236-1239	4.5	6
78	Aspects of the clinical management of hereditary thrombophilia: a personal perspective. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2000</b> , 30 Suppl 2, 11-5		
77	Choice of replacement therapy for hemophilia: recombinant products only?. <i>The Hematology Journal</i> , <b>2000</b> , 1, 72-6		5

76	Gly319 --> arg substitution in the dysfunctional prothrombin Segovia. <i>British Journal of Haematology</i> , <b>1999</b> , 105, 667-9	4.5	12
75	Thrombotic thrombocytopenic purpura: a simpler diagnosis at last?. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 1380-1	7	2
74	Treatment of von Willebrand disease. <i>International Journal of Clinical and Laboratory Research</i> , <b>1998</b> , 28, 211-4		6
73	Treatment of von Willebrand disease. <i>Haemophilia</i> , <b>1998</b> , 4, 661-4	3.3	30
72	Hemostatic drugs. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 245-53	59.2	499
71	Treatment of von Willebrand Disease. <i>Hematology</i> , <b>1998</b> , 3, 339-46	2.2	
70	Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families. <i>Blood</i> , <b>1998</b> , 92, 2353-2358	2.2	307
69	A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 1662-6	9.4	145
68	Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. <i>Blood</i> , <b>1997</b> , 90, 2515-2521	2521	417
67	Partial inhibition of platelet aggregation by nebulized pentamidine in severe haemophiliacs. <i>Haemophilia</i> , <b>1997</b> , 3, 31-4	3.3	1
66	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. <i>Haemophilia</i> , <b>1997</b> , 3, 242-6	3.3	74
65	Resistance to activated protein C in unselected patients with arterial and venous thrombosis. <i>American Journal of Hematology</i> , <b>1997</b> , 55, 59-64	7.1	13
64	Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 77, 0986-0990	7	65
63	Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 813-819	7	6
62	High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 963-964	7	34
61	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. <i>Blood</i> , <b>1997</b> , 90, 2515-2521	2521	65
60	Treatment of von Willebrand's disease. <i>Journal of Internal Medicine Supplement</i> , <b>1997</b> , 740, 129-32		1
59	William Hewson and the blood which issued last but clotted first: the beginning of the story of desmopressin in haemophilia and vWD. <i>Haemophilia</i> , <b>1996</b> , 2, 180-3	3.3	

58	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid. <i>British Journal of Haematology</i> , <b>1996</b> , 92, 733-9	4.5	24
57	Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer's Disease. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 75, 216-218	7	46
56	Frequency of Factor V Arg506 Gin in Italians. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 75, 694-694	7	3
55	Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 477-478	7	13
54	B19 Parvovirus Withstands Super Heating in Antihemophilic Concentrates. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 821-821	7	7
53	The knowledge and perception of factor concentrate in persons with haemophilia A. <i>Haemophilia</i> , <b>1995</b> , 1, 232-5	3.3	1
52	Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. <i>Haemophilia</i> , <b>1995</b> , 1 Suppl 1, 14-20	3.3	5
51	Purinoreceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. <i>British Journal of Haematology</i> , <b>1995</b> , 91, 434-44	4.5	123
50	Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 437-439	7	5
49	The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery [A Meta-Analysis of Double-Blind, Placebo-Controlled Trials. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 1064-1070	7	76
48	Very Low Frequency of Normandy Type Mutations among Type 1 von Willebrand Disease Families. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 73, 324-324	7	4
47	Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 73, 737-738	7	2
46	Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 997-997	7	3
45	Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. <i>British Journal of Haematology</i> , <b>1994</b> , 86, 333-7	4.5	17
44	Repeated Release of the Tissue Factor Pathway Inhibitor. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 72, 327-328		4
43	Antiplatelet Agents in Acute Myocardial Infarction and in the Post-infarction Period. <i>Platelets</i> , <b>1993</b> , 4, 24-5	3.6	
42	Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 270-272	7	54
41	Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. <i>Vox Sanguinis</i> , <b>1993</b> , 64, 197-203	3.1	66



40	Type I von Willebrand disease, subtype 'platelet low': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. <i>British Journal of Haematology</i> , <b>1993</b> , 83, 88-93	4.5	25
39	Modern Treatment of Hemophilia: From the Shadows Towards the Light. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 017-023	7	29
38	Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 0946-0950	7	22
37	Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). <i>British Journal of Haematology</i> , <b>1992</b> , 82, 87-93	4.5	149
36	Sustained correction of the bleeding time in an afibrinogenemic patient after infusion of fresh frozen plasma. <i>British Journal of Haematology</i> , <b>1992</b> , 82, 388-90	4.5	26
35	Intramuscular anti-D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , <b>1992</b> , 80, 337-40	4.5	22
34	Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. <i>Blood</i> , <b>1992</b> , 79, 3130-7	2.2	17
33	Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 310-313	7	26
32	The Effect of Instrumentation on Thromboplastin Calibration. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 588-589	7	12
31	Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. <i>International Journal of Clinical and Laboratory Research</i> , <b>1991</b> , 21, 165-70		37
30	Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 66, 420-425	7	21
29	Adverse Effects of Treatment with Porcine Factor VIII. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 65, 245-247	7	37
28	Restriction of Polymerase Chain Reaction Products for Carrier. <i>Thrombosis and Haemostasis</i> , <b>1990</b> , 63, 527-528	7	2
27	Antibody to Hepatitis G Mrus after a Vapour-Heated Factor VIII Concentrate. <i>Thrombosis and Haemostasis</i> , <b>1990</b> , 64, 232-234	7	21
26	Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis. <i>Thrombosis and Haemostasis</i> , <b>1990</b> , 64, 358-360	7	40
25	Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs. <i>Journal of Medical Virology</i> , <b>1989</b> , 23, 156-8	19.7	5
24	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. <i>American Journal of Hematology</i> , <b>1989</b> , 31, 32-5	7.1	52
23	Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity. <i>American Journal of Hematology</i> , <b>1989</b> , 32, 287-93	7.1	15

22	Monoclonal Antibodies Directed to the Calcium-Free Conformation of Human Protein S. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 708-714	7	11
21	Familial Dysfunction of Protein S. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 763-766	7	27
20	Fibrin(ogen) Peptides in Early Breast Cancer. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 819	7	2
19	Antithrombin Milano, Single Amino Acid Substitution at the Reactive Site, Arg393 to Cys. <i>Thrombosis and Haemostasis</i> , <b>1988</b> , 60, 471-475	7	21
18	EVALUATION OF A FULLY AUTOMATED CENTRIFUGAL ANALYSER FOR ITS PERFORMANCE OF HEMOSTASIS TESTS <b>1987</b> , 58, 0457		
17	Combined Use of DNA Probes in First-Trimester Prenatal Diagnosis of Hemophilia A. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 58, 988-992	7	4
16	Intravenous and Subcutaneous Administration of Desmopressin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 58, 1037-1039	7	62
15	Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 57, 044-048	7	21
14	Laboratory Screening of Inherited Thrombotic Syndromes. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 57, 247-251		51
13	Fibrinogens Milano II and Naples. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 57, 375-375	7	
12	von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. <i>British Journal of Haematology</i> , <b>1986</b> , 63, 703-11	4.5	28
11	Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>1986</b> , 55, 131-135	7	24
10	Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , <b>1986</b> , 55, 246-249	7	11
9	Characterization of an Abnormal Antithrombin (Milano 2) with Defective Thrombin Binding. <i>Thrombosis and Haemostasis</i> , <b>1986</b> , 56, 349-352	7	2
8	Charge heterogeneity of human protein C revealed by isoelectric focusing in immobilized pH gradients. <i>Electrophoresis</i> , <b>1985</b> , 6, 373-376	3.6	12
7	Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. <i>Lancet, The</i> , <b>1985</b> , 1, 271-2	4.0	74
6	Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. <i>Lancet, The</i> , <b>1985</b> , 2, 1-4	4.0	154
5	Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) Effects of Acetylsalicylic Acid and External Ionized Calcium. <i>Thrombosis and Haemostasis</i> , <b>1985</b> , 53, 221-224	7	12

4	Hemostatic Functions in Hypoalpha and Hyperbetalipoproteinemias. <i>Thrombosis and Haemostasis</i> , <b>1983</b> , 50, 624-625	7	5
3	Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. <i>Thrombosis and Haemostasis</i> , <b>1982</b> , 47, 084-089	7	75
2	The Molecular Basis of Von Willebrand Disease233-245		3
1	The Use of Plasma-Derived Concentrates200-206		4